Year All202420232022202120202019201820172016201520142013 June 21, 2024 Arvinas Announces Presentations for Two of its PROTAC® Investigational Programs Targeting BCL6 and LRRK2 Read more June 17, 2024 Arvinas Announces Promotions of Ian Taylor, Ph.D. to President of Research and Development and Angela Cacace, Ph.D. to Chief Scientific Officer Read more June 3, 2024 Arvinas to Participate in Upcoming Investor Conferences Read more May 23, 2024 Arvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress Read more May 16, 2024 Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) Read more May 9, 2024 Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress Read more May 7, 2024 Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update Read more May 2, 2024 Arvinas to Present at Upcoming Investor Conferences Read more April 24, 2024 Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer Read more April 11, 2024 Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer Read more
June 21, 2024 Arvinas Announces Presentations for Two of its PROTAC® Investigational Programs Targeting BCL6 and LRRK2 Read more
June 17, 2024 Arvinas Announces Promotions of Ian Taylor, Ph.D. to President of Research and Development and Angela Cacace, Ph.D. to Chief Scientific Officer Read more
May 23, 2024 Arvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress Read more
May 16, 2024 Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) Read more
May 9, 2024 Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress Read more
May 7, 2024 Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update Read more
April 11, 2024 Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer Read more
